Sat, Dec 20, 2014, 10:04 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • breezerwave breezerwave Dec 7, 2012 4:02 AM Flag

    Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

    According to the Exelixis website and the clinical trial listing, this study information was last updated May 2012 and trial is estimated due to be completed December 2012.

    Here is the purpose:

    "The purpose of this study is to determine whether or not XL184 demonstrates anti-tumor activity in selected tumor types under a randomized discontinuation trial (RDT) design. Subjects who have responded to study drug after 12 weeks of open-label XL184 administration will continue to take XL184. Subjects who are clearly progressing will discontinue study treatment and subjects who demonstrate stable disease will be randomized to either XL184 or placebo. For individual patients, once disease progression is observed, the blind will be broken and subjects who were randomized to placebo will be offered the option to receive open-label XL184. Subjects who progressed while taking XL184 will discontinue study treatment.

    Emerging data may support enrollment in an open-label, non-randomized expansion cohort (NRE). There will be NRE cohorts for prostate and ovarian cancers."

    Given that cabo was proven effective in MTC it seems that cabo should show results in cancers located in other parts of a person's body.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "According to the Exelixis website and the clinical trial listing, this study information was last updated May 2012 and trial is estimated due to be completed December 2012."

      Results already presented. The remaining ongoing portion of this trial is the low dose (4omg) expansion of the CRPC NRE cohort which was used to develop the protocols for Comet 1&2

    • Estimated Study Completion Date: December 2012
      Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)

      Sentiment: Strong Buy

 
EXEL
1.33-0.02(-1.48%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
3M Company
NYSEFri, Dec 19, 2014 4:04 PM EST
Southwestern Energy Co.
NYSEFri, Dec 19, 2014 4:05 PM EST